Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a spruce extract cream soothe sensitive skin? new study says maybe.

NCT ID NCT07573592

Symptom relief Sponsor: Repolar Pharmaceuticals Oy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a cream made with spruce tree extract can help repair the skin barrier and reduce symptoms like dryness, redness, and itching in people with sensitive, atopy-prone skin. 66 healthy adults used the cream or a placebo for 21 days. Researchers measured skin moisture loss, hydration, and signs of irritation to see if the cream worked better than the placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

66 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male and female subjects aged 18 to 60 years. * Caucasian ethnicity. * Subjects with atopy-prone skin on cheekbones and forearms, characterized by sensitive/reactive skin, redness, or itching. * Transepidermal water loss (TEWL) thresholds at screening: Cheekbones ≥ 20 g/m\^2/h and Forearms ≥10 g/m\^2/h. * Stable pharmacological therapy for at least one month without planned changes. * Subjects aware of study procedures and having signed an informed consent form. Exclusion Criteria: * Acute or chronic diseases liable to interfere with study data or subject safety. * Participation in other clinical trials or insufficient washout period (14 days). * Known hypersensitivity or allergy to any ingredients in the test products. * Use of pharmacological treatments considered incompatible with the study requirements. * Presence of skin diseases that could interfere with instrumental measurements. * Pregnant or breastfeeding women, or women of childbearing potential unwilling to use precautions to avoid pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic IgE-mediated allergic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPY Skin barrier to water loss

Contacts and locations

Locations

  • Complife Italia S.r.l

    San Martino Siccomario, Pavia, 27028, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.